The Roche director warns that the reduction of drug prices in the USA will lead to price increases in Switzerland and other countries, affecting the accessibility of treatments.

Thomas Schinecker, the CEO of Roche, stated that recent agreements between the Trump administration and pharmaceutical companies to reduce drug prices in the US will have global repercussions, with anticipated price increases in Switzerland and other countries. These agreements aim to reduce prices for the Medicaid program but will also impose price control mechanisms that will affect international markets. Schinecker emphasized that although prices will not rise immediately, it is expected that every new treatment will be more expensive outside the US. The UK has already agreed to pay more for medications, and other countries, including Switzerland, are in discussions with manufacturers to avoid tariffs. The agreements with pharmaceutical companies also involve commitments for significant investments in research and development in the US.